India, Oct. 13 -- Caspian Therapeutics and Kura Oncology (KURA) outlined the development strategy for KO-7246, an oral menin inhibitor designed for diabetes and other chronic metabolic diseases. The companies highlighted new findings supporting the candidate's potential to restore the body's insulin-producing capacity.
Diabetes is characterized by inadequate insulin production or ineffective insulin use, leading to elevated blood sugar levels. According to the companies, menin inhibition may offer a novel approach by increasing the number of insulin-producing beta cells in the pancreas.
KO-7246 is a selective orally available menin inhibitor currently in IND-enabling development. Caspian plans to advance the candidate into a Phase 1 clini...